OK, boomer: You ’re not the only one who needs testing for hepatitis C
It turns out that many more people than just boomers can benefit from testing for hepatitis C, a viral infection of the liver that often causes no symptoms. If you’re a member of the baby-boom generation (born between 1946 and 1964), your doctor may have already recommended the test. But those born before or after those years may not have known about the test unless they had a risk factor for hepatitis C, such as a history of intravenous drug use. A new guideline is changing this approach. Why the different recommendations for baby boomers? In 2012–2013, the CDC and the US Preventive Services Task Force (USPSTF) established guidelines that recommended all baby boomers be screened for hepatitis C. Boomers were singled out because this population had most of the undiagnosed infections. Screening for hepatitis C is a big deal, because it’s a potentially serious and treatable infection affecting an estimated four million persons in the US and 100 million people worldwide. And, while it’s common to have it without knowing it, liver failure or liver cancer are known complications that could be prevented by screening and treatment. Studies looking at the effectiveness of screening baby boomers have demonstrated success as well as limitations. In recent years it’s become clear that the fastest growing group of people newly infected with hepatitis C is young adults ages 20 to 39 who would be missed under previous guidelines. Why not screen everyone? That&...
Publication date: Available online 2 June 2020Source: Pathology - Research and PracticeAuthor(s): Hyeongjoo Kim, Taewan Kim, Gunn Jaygal, Jongsoo Woo, Chang-Jin Kim, Moo-Jun Baek, Dongjun Jeong
ABSTRACT Objective To assess the outcome of an educational nutritional intervention in the quality of diet of women with breast cancer in adjuvant treatment. Methods Women with breast cancer and admitted for surgical treatment were divided in an intervention group (n=18) and a comparison group (n=78), and participated in a nonrandomized clinical trial. Participants were assessed before and after the treatment and/or intervention. A food frequency questionnaire was applied and the quality of diet was calculated using the Brazilian Healthy Eating Index Revised. The educational nutritional intervention lasted 12 months and wa...
Publication date: Available online 2 June 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Tingjing Zhang, Shanshan Bian, Yeqing Gu, Ge Meng, Qing Zhang, Li Liu, Hongmei Wu, Shunming Zhang, Yawen Wang, Xuena Wang, Xingqi Cao, Huiping Li, Yunyun Liu, Xiaoyue Li, Xiaohe Wang, Shaomei Sun, Xing Wang, Ming Zhou, Huanli Jiao, Qiyu Jia
Publication date: Available online 2 June 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Hye-Kyung Chung, Ji Sun Nam, Mi-Yeon Lee, Yong-Bum Kim, Yu-Sam Won, Won-Jun Song, Young-Hwan Kim, Chul Woo Ahn, Ki-Chul Sung
The United States should have 100 million doses of one candidate coronavirus vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a member of the White House Coronavirus Task Force, said Tuesday.
The Trump administration chose 5 companies as the most likely to produce a vaccine. The tally of new cases is rising in the U.S., partly because of expanded testing. Italy ends travel restrictions.
A senior U.S. Army vaccine researcher said on Tuesday it was reasonable to expect that some sort of coronavirus vaccine could be available to part of the U.S. population by the end of the year.Reuters Health Information
Bigfoot Biomedical hasn't let the coronavirus pandemic stand in the way of bringing itsÂ injection-based digitized insulin dosing platform to the U.S. market. If anything, CEO Jeffrey Brewer says the pandemic has "only crystalized the need for medical solutions like ours that facilitate remote care, remote support, and home delivery." The company has raised a total of $55 million to close its series C equity financing.Â Abbott led the round with support from existing investors, including Quadrant Capital Advisors, Senvest Capital, Janus Henderson, and Cormorant Asset Management, along with n...
This study aimed to analyze clinical and laboratory parameters and their association with long-term outcomes in patients who underwent liver transplantation for hepatocellular carcinoma treatment, according to the etiology of the underlying chronic liver disease, in order to identify predictors of response to this therapeutic modality. METHODS: Demographic, clinical, and laboratory data from a cohort of 134 patients who underwent orthotopic liver transplantation for hepatocellular carcinoma treatment at a referral center in Brazil were retrospectively selected and compared according to the etiologic group of the underlying...
The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
More News: AIDS Vaccine | Alcoholism | Babies | Bile | Blogging | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Vaccines | Cirrhosis | Harvard | Health | Hepatitis | Hepatitis A | Hepatitis B | Hepatitis C | Hepatitis Vaccine | HIV AIDS | Infectious Diseases | Insurers | Iron | Liver | Liver Disease | Study | Sugar | Ultrasound | Urology & Nephrology | Vaccines | Women